Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Leemann

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Schweizerische Medizinische Wochenschrift|December 12, 1992
[Q-DIPS: current approach to prediction of drug interactions]T Leemann, P Dayer
Life Sciences|January 1, 1994
Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxideT Leemann, P Bonnabry, P Dayer
Life Sciences|January 1, 1991
The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitroS Ferrari, T Leemann, P Dayer
European Journal of Clinical Pharmacology|January 1, 1996
Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicamP Bonnabry, T Leemann, P Dayer
Clinical Pharmacology and Therapeutics|January 1, 1989
Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activityP Dayer, T Leemann, R Striberni
European Journal of Clinical Pharmacology|January 1, 1996
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitorsC Transon, T Leemann, P Dayer
Therapeutische Umschau. Revue Therapeutique|December 1, 1985
[Drug interactions in the elderly]J Fabre, P Dayer, T Leemann
Life Sciences|January 1, 1992
In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450J Zhao, T Leemann, P Dayer
Life Sciences|January 1, 1993
Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liverT Leemann, C Transon, P Dayer
Schweizerische Medizinische Wochenschrift|December 5, 1987
[Evaluation of a caffeine test for determining the phenotype of N-acetyltransferase]M P Gascon, T Leemann, P Dayer
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Schweizerische Medizinische Wochenschrift|December 12, 1992
[Q-DIPS: current approach to prediction of drug interactions]T Leemann, P Dayer
Life Sciences|January 1, 1994
Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxideT Leemann, P Bonnabry, P Dayer
Life Sciences|January 1, 1991
The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitroS Ferrari, T Leemann, P Dayer
European Journal of Clinical Pharmacology|January 1, 1996
Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicamP Bonnabry, T Leemann, P Dayer
Clinical Pharmacology and Therapeutics|January 1, 1989
Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activityP Dayer, T Leemann, R Striberni
European Journal of Clinical Pharmacology|January 1, 1996
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitorsC Transon, T Leemann, P Dayer
Therapeutische Umschau. Revue Therapeutique|December 1, 1985
[Drug interactions in the elderly]J Fabre, P Dayer, T Leemann
Life Sciences|January 1, 1992
In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450J Zhao, T Leemann, P Dayer
Life Sciences|January 1, 1993
Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liverT Leemann, C Transon, P Dayer
Schweizerische Medizinische Wochenschrift|December 5, 1987
[Evaluation of a caffeine test for determining the phenotype of N-acetyltransferase]M P Gascon, T Leemann, P Dayer
Pageof 3